Karyopharm Therapeutics aims to price initial public offering of stock

BofA Merrill Lynch, Leerink Swann are the joint bookrunning managers

By Devika Patel

Knoxville, Tenn., Oct. 4 - Karyopharm Therapeutics Inc. will conduct an initial public offering of its common stock with a 30-day greenshoe option, according to a Form S-1 filed Friday with the Securities and Exchange Commission.

BofA Merrill Lynch and Leerink Swann are the joint bookrunning managers. JMP Securities and Oppenheimer & Co. are the co-managers.

Proceeds will be used for clinical development of the company's lead drug candidate, Selinexor, preclinical development of its drug candidates for anti-inflammatory, viral and wound-healing indications, discovery, research, preclinical development and clinical trials of additional drug candidates, working capital and other general corporate purposes.

The clinical-stage pharmaceutical company is based in Natick, Mass. It intends to list its common stock on the Nasdaq under the symbol "KPTI."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.